Clinical Trial Update: Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of roflumilast and alogliptin for proof-of-mechanism in type 2 diabetes; results have been posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Alogliptin (alogliptin)
• Roflumilast (roflumilast)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 1 | Status: COMPLETED | Results posted: 2014-02-20